Elmind Capital LP Buys New Stake in Summit Therapeutics PLC $SMMT

Posted by Brenda Bartman on Aug 26th, 2026

Elmind Capital LP bought a new stake in Summit Therapeutics PLC (NASDAQ:SMMT – Free Report) in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 493,820 shares of the company’s stock, valued at approximately $7,194,957. Summit Therapeutics accounts for about 0.0% of Elmind Capital LP’s investment portfolio, making the stock its 17th biggest holding. Elmind Capital LP owned about 0.06% of Summit Therapeutics as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in shares of Summit Therapeutics by 1.1% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 65,411 shares of the company’s stock valued at $1,273,000 after purchasing an additional 694 shares during the last quarter. Fifth Third Bancorp boosted its holdings in shares of Summit Therapeutics by 24.4% during the 1st quarter. Fifth Third Bancorp now owns 3,732 shares of the company’s stock valued at $71,000 after acquiring an additional 732 shares in the last quarter. Sei Investments Co. lifted its position in shares of Summit Therapeutics by 3.3% during the 3rd quarter. Sei Investments Co. now owns 27,163 shares of the company’s stock valued at $561,000 after acquiring an additional 860 shares during the period. Levin Capital Strategies L.P. grew its holdings in shares of Summit Therapeutics by 2.7% in the fourth quarter. Levin Capital Strategies L.P. now owns 37,676 shares of the company’s stock valued at $659,000 after acquiring an additional 1,000 shares in the last quarter. Finally, State of Wisconsin Investment Board boosted its position in shares of Summit Therapeutics by 1.1% in the fourth quarter. State of Wisconsin Investment Board now owns 92,882 shares of the company’s stock valued at $1,625,000 after acquiring an additional 1,047 shares during the period. 4.61% of the stock is owned by institutional investors and hedge funds.

Summit Therapeutics Stock Down 4.1%

NASDAQ SMMT traded down $0.59 during trading hours on Friday, reaching $13.74. The company’s stock had a trading volume of 2,922,318 shares, compared to its average volume of 4,157,646. Summit Therapeutics PLC has a 1 year low of $12.07 and a 1 year high of $29.23. The company has a market capitalization of $10.96 billion, a price-to-earnings ratio of -12.27 and a beta of -1.23. The firm’s 50-day moving average price is $14.12 and its 200-day moving average price is $16.17.

Summit Therapeutics (NASDAQ:SMMT – Get Free Report) last posted its earnings results on Thursday, July 23rd. The company reported ($0.28) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.27) by ($0.01). Equities research analysts anticipate that Summit Therapeutics PLC will post -1.2 EPS for the current fiscal year.

Wall Street Analyst Weigh In

SMMT has been the topic of several research reports. Leerink Partners raised Summit Therapeutics from an “underperform” rating to a “market perform” rating and raised their target price for the stock from $12.00 to $13.00 in a research report on Wednesday, August 12th. Summit Redstone set a $11.90 target price on shares of Summit Therapeutics in a research note on Tuesday. KeyCorp reiterated an “overweight” rating on shares of Summit Therapeutics in a report on Monday, June 1st. Wall Street Zen cut shares of Summit Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, July 18th. Finally, HC Wainwright reiterated a “neutral” rating on shares of Summit Therapeutics in a report on Wednesday. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, eight have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Summit Therapeutics presently has an average rating of “Hold” and an average target price of $24.07.

Get Our Latest Analysis on Summit Therapeutics

Insider Activity

In other news, CEO Mahkam Zanganeh acquired 3,810,000 shares of the business’s stock in a transaction that occurred on Friday, June 12th. The stock was acquired at an average price of $13.12 per share, with a total value of $49,987,200.00. Following the completion of the transaction, the chief executive officer directly owned 573,883,879 shares of the company’s stock, valued at $7,529,356,492.48. This trade represents a 0.67% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Manmeet Singh Soni bought 50,000 shares of the business’s stock in a transaction that occurred on Thursday, June 4th. The shares were bought at an average cost of $14.45 per share, for a total transaction of $722,500.00. Following the transaction, the chief financial officer owned 3,123,603 shares of the company’s stock, valued at $45,136,063.35. The trade was a 1.63% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders acquired 7,870,000 shares of company stock worth $103,616,900 over the last quarter. Corporate insiders own 83.50% of the company’s stock.

About Summit Therapeutics

(Free Report)

Summit Therapeutics plc is a clinical‐stage biotechnology company dedicated to the discovery and development of precision medicines for serious and life‐threatening diseases. The company applies a targeted approach to drug design, focusing on novel mechanisms of action that differentiate its candidates from existing therapies.

Summit’s lead asset, ridinilazole (formerly SMT19969), is being developed to treat Clostridioides difficile infections and has received both Fast Track and Qualified Infectious Disease Product designations from the U.S.